USD 4.52
↑ 0.45 (11.06%)
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| NVRO | 11.1 | -12.1 | -11.0 | -19.1 | -59.5 | -73.3 | -95.3 | -95.7 | -83.8 | -82.1 |
| S&P 500 | -1.3 | -2.3 | 0.5 | 5.7 | 10.8 | 30.2 | 24.9 | 88.0 | 187.6 | 33142.5 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | NVRO |
| name | Nevro Corp. |
| price | 4.52 |
| changes percentage | 11.06 |
| change | 0.45 |
| day low | 3.96 |
| day high | 4.57 |
| year high | 22.64 |
| year low | 3.96 |
| market cap | 169371632 |
| price avg 50 | 5.19 |
| price avg 200 | 9.51 |
| exchange | NYSE |
| volume | 1397849 |
| avg volume | 548732 |
| open | 4.08 |
| previous close | 4.07 |
| eps | -1.87 |
| pe | -2.42 |
| earnings announcement | 2025-02-19T05:00:00.000+0000 |
| shares outstanding | 37471600 |
| timestamp | 2024-11-15 21:00:02 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001444380 | |||
| revenue | 425174000 | 406365000 | 4.63 |
| gross profit | 290060000 | 276367000 | 4.95 |
| gross profit ratio | 0.68 | 0.68 | 0.31 |
| research and development expenses | 54418000 | 53065000 | 2.55 |
| operating expenses | 389368000 | 375203000 | 3.78 |
| interest income | 14166000 | 4021000 | 252.30 |
| interest expense | 8014000 | 6432000 | 24.60 |
| ebitda | -78310000 | 21023000 | -472.50 |
| ebitdaratio | -0.18 | -0.5 | 63.28 |
| operating income | -99308000 | -98836000 | -0.48 |
| operating income ratio | -0.23 | -0.24 | 3.97 |
| net income | -92213000 | 3001000 | -3,172.74 |
| net income ratio | -0.22 | 0.01 | -3,036.81 |
| eps | -2.56 | 0.09 | -3,111.76 |
Revenue Growth: revenue increased to 425 million in 2023 from 406 million in 2022 representing a change of 4.63%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 290 million in 2023 from 276 million in 2022 representing a change of 4.95%. This indicates a sales profitability growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 54 million in 2023 from 53 million in 2022 representing a change of 2.55%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
Operating Income: Operating income increased to -99 million in 2023 from -99 million in 2022 representing a change of -0.48%. The increase in operating income indicates better operational performance and increased profitability.
Operating Expenses: Operating Expenses increased to 389 million in 2023 from 375 million in 2022 representing a change of 3.78%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -78 million in 2023 from 21 million in 2022 representing a change of -472.5%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Net Income: Net income decreased to -92 million in 2023 from 3 million in 2022 representing a change of -3172.74%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to -2.56 in 2023 from -2.56 in 2022 representing a change of -3111.76%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001444380 | |||
| revenue | 96910000 | 104161000 | -6.96 |
| gross profit | 64614000 | 67467000 | -4.23 |
| gross profit ratio | 0.67 | 0.65 | 2.94 |
| research and development expenses | 10579000 | 14117000 | -25.06 |
| operating expenses | 79050000 | 92588000 | -14.62 |
| interest income | 3226000 | 3317000 | -2.74 |
| interest expense | -7008000 | 6741000 | -203.96 |
| ebitda | -13866000 | -9001000 | -54.05 |
| ebitdaratio | -0.14 | -0.09 | -65.58 |
| operating income | -13866000 | -25121000 | 44.80 |
| operating income ratio | -0.14 | -0.24 | 40.67 |
| net income | -15344000 | -19575000 | 21.61 |
| net income ratio | -0.16 | -0.19 | 15.75 |
| eps | -0.41 | -0.53 | 22.64 |
Revenue Growth: revenue increased to 97 million in 2024Q3 from 104 million in 2024Q2 representing a change of -6.96%. This indicates a sales growth, which is a positive sign for the company.
Operating Expenses: Operating Expenses decreased to 79 million in 2024Q3 from 93 million in 2024Q2 representing a change of -14.62%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
Earnings per Share (EPS): EPS increased to -0.41 in 2024Q3 from -0.41 in 2024Q2 representing a change of 22.64%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Gross Profit: Gross Profit decreased to 65 million in 2024Q3 from 67 million in 2024Q2 representing a change of -4.23%. This indicates a sales profitability decline, which is a negative sign for the company.
Research and Development (R&D) Expenses: R&D Expenses decreased to 11 million in 2024Q3 from 14 million in 2024Q2 representing a change of -25.06%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -14 million in 2024Q3 from -9 million in 2024Q2 representing a change of -54.05%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income decreased to -14 million in 2024Q3 from -25 million in 2024Q2 representing a change of 44.8%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to -15 million in 2024Q3 from -20 million in 2024Q2 representing a change of 21.61%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001444380 | |||
| total assets | 635713000 | 602408000 | 5.53 |
| total liabilities | 342568000 | 278532000 | 22.99 |
| total equity | 293145000 | 323876000 | -9.49 |
| cash and cash equivalents | 104217000 | 120373000 | -13.42 |
| short term investments | 218506000 | 254012000 | -13.98 |
| long term investments | 0 | 606000 | -100.00 |
| total current assets | 530921000 | 562937000 | -5.69 |
| total non current assets | 104792000 | 39471000 | 165.49 |
| total current liabilities | 83375000 | 79212000 | 5.26 |
| total non current liabilities | 259193000 | 199320000 | 30.04 |
| common stock | 36000 | 35000 | 2.86 |
| retained earnings | -699410000 | -607197000 | -15.19 |
| total debt | 221827000 | 197163000 | 12.51 |
Total Assets: Total Assets increased to 636 million in 2023 from 602 million in 2022 representing a change of 5.53%. Suggesting a growth in asset holdings.
Common Stock: Common Stock increased to 0 in 2023 from 0 in 2022 representing a change of 2.86%. This indicates an increase in ownership interest.
Total Liabilities: Total Liabilities increased to 343 million in 2023 from 279 million in 2022 representing a change of 22.99%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to 293 million in 2023 from 324 million in 2022 representing a change of -9.49%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 104 million in 2023 from 120 million in 2022 representing a change of -13.42%. This indicates a decrease in available liquid assets.
Short Term Investments: Short Term Investments decreased to 219 million in 2023 from 254 million in 2022 representing a change of -13.98%. This indicates a decrease in short-term investment holdings.
Total Current Assets: Total Current Assets decreased to 531 million in 2023 from 563 million in 2022 representing a change of -5.69%. This indicates a worsen liquidity position.
Total Current Liabilities: Total Current Liabilities increased to 83 million in 2023 from 79 million in 2022 representing a change of 5.26%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -699 million in 2023 from -607 million in 2022 representing a change of -15.19%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 222 million in 2023 from 197 million in 2022 representing a change of 12.51%. This indicates an increase in overall debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001444380 | |||
| total assets | 595648000 | 603335000 | -1.27 |
| total liabilities | 322005000 | 329082000 | -2.15 |
| total equity | 273643000 | 274253000 | -0.22 |
| cash and cash equivalents | 71982000 | 74702000 | -3.64 |
| short term investments | 205056000 | 198991000 | 3.05 |
| long term investments | 0 | 0 | NaN |
| total current assets | 479240000 | 486187000 | -1.43 |
| total non current assets | 116408000 | 117148000 | -0.63 |
| total current liabilities | 95413000 | 101934000 | -6.40 |
| total non current liabilities | 226592000 | 227148000 | -0.24 |
| common stock | 37000 | 37000 | 0.00 |
| retained earnings | -759738000 | -744394000 | -2.06 |
| total debt | 246591000 | 242658000 | 1.62 |
Total Assets: Total Assets decreased to 596 million in 2024Q3 from 603 million in 2024Q2 representing a change of -1.27%. Suggesting a decrease in asset holdings.
Total Equity: Total Equity decreased to 274 million in 2024Q3 from 274 million in 2024Q2 representing a change of -0.22%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 72 million in 2024Q3 from 75 million in 2024Q2 representing a change of -3.64%. This indicates a decrease in available liquid assets.
Total Current Assets: Total Current Assets decreased to 479 million in 2024Q3 from 486 million in 2024Q2 representing a change of -1.43%. This indicates a worsen liquidity position.
Retained Earnings: Retained Earnings decreased to -760 million in 2024Q3 from -744 million in 2024Q2 representing a change of -2.06%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 247 million in 2024Q3 from 243 million in 2024Q2 representing a change of 1.62%. This indicates an increase in overall debt burden.
Total Liabilities: Total Liabilities decreased to 322 million in 2024Q3 from 329 million in 2024Q2 representing a change of -2.15%. This indicates a decrease in overall liabilities.
Short Term Investments: Short Term Investments increased to 205 million in 2024Q3 from 199 million in 2024Q2 representing a change of 3.05%. This indicates an increase in short-term investment holdings.
Total Current Liabilities: Total Current Liabilities decreased to 95 million in 2024Q3 from 102 million in 2024Q2 representing a change of -6.4%. This indicates a lower short-term debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001444380 | |||
| net change in cash | -16156000 | 85663000 | -118.86 |
| operating cash flow | -58829000 | 24675000 | -338.42 |
| free cash flow | -67423000 | 17133000 | -493.53 |
| capital expenditure | -8594000 | -7542000 | -13.95 |
| depreciation and amortization | 11535000 | 10327000 | 11.70 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 56866000 | 56798000 | 0.12 |
| accounts payables | -4923000 | -5646000 | 12.81 |
| inventory | -19235000 | -7828000 | -145.72 |
| acquisitions net | -38022000 | -64290000 | 40.86 |
| investments in property plant and equipment | -8594000 | -7542000 | -13.95 |
| net cash used for investing activites | -7204000 | 64290000 | -111.21 |
| debt repayment | 53598000 | 0 | NaN |
| common stock issued | 6540000 | 6393000 | 2.30 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 49534000 | -2457000 | 2,116.04 |
| cash at end of period | 104823000 | 120979000 | -13.35 |
| accounts receivables | -211000 | -9611000 | 97.80 |
| cash at beginning of period | 120979000 | 35316000 | 242.56 |
Net Change in Cash: Net Change in Cash decreased to -16 million in 2023 from 86 million in 2022 representing a change of -118.86%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow decreased to -59 million in 2023 from 25 million in 2022 representing a change of -338.42%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -67 million in 2023 from 17 million in 2022 representing a change of -493.53%. This indicates a decrease in cash generated after accounting for capital expenditures.
Stock-Based Compensation: Stock-Based Compensation increased to 57 million in 2023 from 57 million in 2022 representing a change of 0.12%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Receivables: Accounts Receivables increased to 0 in 2023 from -10 million in 2022 representing a change of 97.8%. This suggests that the company is less capable of collecting payments from its customers.
Capital Expenditure: Capital Expenditure decreased to -9 million in 2023 from -8 million in 2022 representing a change of -13.95%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Accounts Payables: The absolute value of Accounts Payables decreased to 5 million in 2023 from 6 million in 2022 representing a change of 12.81%. This indicates that the company has reduced its outstanding obligations to its suppliers.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001444380 | |||
| operating cash flow | 3060000 | -8173000 | 137.44 |
| free cash flow | 489000 | -10540000 | 104.64 |
| capital expenditure | -2571000 | -2430000 | -5.80 |
| depreciation and amortization | 1059000 | 3571000 | -70.34 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 11423000 | 14421000 | -20.79 |
| accounts receivables | 3331000 | 2355000 | 41.44 |
| accounts payables | -2663000 | 2293000 | -216.14 |
| inventory | 9210000 | -5402000 | 270.49 |
| acquisitions net | 0 | -205000 | 100.00 |
| investments in property plant and equipment | -2571000 | -2430000 | -5.80 |
| net cash used for investing activites | -6435000 | -9528000 | 32.46 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 0 | 2722000 | -100.00 |
| common stock repurchased | 1913000 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | -682000 | 1997000 | -134.15 |
| net change in cash | -2114000 | -15601000 | 86.45 |
| cash at end of period | 72588000 | 74702000 | -2.83 |
| cash at beginning of period | 74702000 | 90303000 | -17.28 |
Net Change in Cash: Net Change in Cash increased to -2 million in 2024Q3 from -16 million in 2024Q2 representing a change of 86.45%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to 3 million in 2024Q3 from -8 million in 2024Q2 representing a change of 137.44%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to 0 million in 2024Q3 from -11 million in 2024Q2 representing a change of 104.64%. This indicates an increase in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure decreased to -3 million in 2024Q3 from -2 million in 2024Q2 representing a change of -5.8%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Stock-Based Compensation: Stock-Based Compensation decreased to 11 million in 2024Q3 from 14 million in 2024Q2 representing a change of -20.79%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables increased to 3 million in 2024Q3 from 2 million in 2024Q2 representing a change of -216.14%. This indicates that the company has increased its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables increased to 3 in 2024Q3 from 2 million in 2024Q2 representing a change of 41.44%. This suggests that the company is less capable of collecting payments from its customers.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 11.82 | 11.51 | 2.70 |
| net income per share | -2.56 | 0.08 | -3,116.06 |
| operating cash flow per share | -1.63 | 0.7 | -334.02 |
| free cash flow per share | -1.87 | 0.49 | -486.27 |
| cash per share | 8.97 | 10.6 | -15.39 |
| book value per share | 8.15 | 9.17 | -11.16 |
| tangible book value per share | 6.33 | 9.17 | -31.01 |
| shareholders equity per share | 8.15 | 9.17 | -11.16 |
| interest debt per share | 6.1 | 5.47 | 11.45 |
| market cap | 774320395.12 | 1398578702.4 | -44.64 |
| enterprise value | 891930395.12 | 1475368702.4 | -39.55 |
| pe ratio | -8.4 | 466.04 | -101.80 |
| price to sales ratio | 1.82 | 3.44 | -47.08 |
| pocfratio | -13.16 | 56.68 | -123.22 |
| pfcf ratio | -11.48 | 81.63 | -114.07 |
| pb ratio | 2.64 | 4.32 | -38.83 |
| ptb ratio | 2.64 | 4.32 | -38.83 |
| ev to sales | 2.1 | 3.63 | -42.22 |
| enterprise value over ebitda | -11.39 | 70.18 | -116.23 |
| ev to operating cash flow | -15.16 | 59.79 | -125.36 |
| ev to free cash flow | -13.23 | 86.11 | -115.36 |
| earnings yield | -0.12 | 0.0 | -5,649.99 |
| free cash flow yield | -0.09 | 0.01 | -810.79 |
| debt to equity | 0.72 | 0.58 | 25.03 |
| debt to assets | 0.33 | 0.31 | 7.24 |
| net debt to ebitda | -1.5 | 3.65 | -141.12 |
| current ratio | 6.37 | 7.11 | -10.40 |
| interest coverage | -12.39 | -15.37 | 19.36 |
| income quality | 0.64 | 8.22 | -92.24 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0.13 | 0.13 | -1.99 |
| intangibles to total assets | 0.1 | 0 | NaN |
| capex to operating cash flow | -0.15 | 0.31 | -147.79 |
| capex to revenue | 0.02 | 0.02 | 8.91 |
| capex to depreciation | 0.75 | 0.73 | 2.02 |
| stock based compensation to revenue | 0.13 | 0.14 | -4.31 |
| graham number | 21.67 | 4.19 | 417.64 |
| roic | -0.19 | -0.14 | -36.16 |
| return on tangible assets | -0.16 | 0.0 | -3,346.34 |
| graham net net | 2.75 | 5.8 | -52.56 |
| working capital | 447546000 | 483725000 | -7.48 |
| tangible asset value | 227627000 | 323876000 | -29.72 |
| net current asset value | 188353000 | 284405000 | -33.77 |
| invested capital | 546576000 | 519426000 | 5.23 |
| average receivables | 79153500 | 74702500 | 5.96 |
| average payables | 24684500 | 29424000 | -16.11 |
| average inventory | 109157000 | 96577500 | 13.03 |
| days sales outstanding | 68.14 | 70.9 | -3.88 |
| days payables outstanding | 60.84 | 75.38 | -19.30 |
| days of inventory on hand | 320.59 | 279.76 | 14.60 |
| receivables turnover | 5.36 | 5.15 | 4.04 |
| payables turnover | 6.0 | 4.84 | 23.91 |
| inventory turnover | 1.14 | 1.3 | -12.74 |
| roe | -0.31 | 0.01 | -3,494.86 |
| capex per share | 0.24 | 0.21 | 11.85 |
ROE: Return on Equity (ROE) decreased to -0.31 on 2023-12-31 from 0.01 on 2022-12-31, representing a change of -3494.86%. Suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -8.40 on 2023-12-31 from 466.04 on 2022-12-31, representing a change of -101.80%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 6.37 on 2023-12-31 from 7.11 on 2022-12-31, representing a change of -10.40%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.72 on 2023-12-31 from 0.58 on 2022-12-31, representing a change of 25.03%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| NVRO | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 2.6 | 2.82 | -7.93 |
| net income per share | -0.41 | -0.53 | 22.43 |
| operating cash flow per share | 0.08 | -0.22 | 137.05 |
| free cash flow per share | 0.01 | -0.29 | 104.59 |
| cash per share | 7.42 | 7.41 | 0.17 |
| book value per share | 7.33 | 7.42 | -1.26 |
| tangible book value per share | 5.63 | 5.69 | -0.98 |
| shareholders equity per share | 7.33 | 7.42 | -1.26 |
| interest debt per share | 6.42 | 6.1 | 5.31 |
| market cap | 208646230.13 | 318026424.87 | -34.39 |
| enterprise value | 383255230.13 | 485982424.87 | -21.14 |
| pe ratio | -3.4 | -4.06 | 16.30 |
| price to sales ratio | 2.15 | 3.05 | -29.48 |
| pocfratio | 68.19 | -38.91 | 275.23 |
| pfcf ratio | 426.68 | -30.17 | 1,514.10 |
| pb ratio | 0.76 | 1.16 | -34.25 |
| ptb ratio | 0.76 | 1.16 | -34.25 |
| ev to sales | 3.95 | 4.67 | -15.24 |
| enterprise value over ebitda | -27.64 | -53.99 | 48.81 |
| ev to operating cash flow | 125.25 | -59.46 | 310.63 |
| ev to free cash flow | 783.75 | -46.11 | 1,799.81 |
| earnings yield | -0.07 | -0.06 | -19.48 |
| free cash flow yield | 0.0 | -0.03 | 107.07 |
| debt to equity | 0.9 | 0.8 | 13.16 |
| debt to assets | 0.41 | 0.36 | 14.37 |
| net debt to ebitda | -12.59 | -18.66 | 32.51 |
| current ratio | 5.02 | 4.77 | 5.31 |
| interest coverage | 1.98 | -3.73 | 153.09 |
| income quality | -0.2 | 0.42 | -147.76 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0.11 | 0.14 | -19.45 |
| intangibles to total assets | 0.11 | 0.11 | 0.13 |
| capex to operating cash flow | 0.84 | -0.3 | 382.59 |
| capex to revenue | 0.03 | 0.02 | 13.72 |
| capex to depreciation | 2.43 | 0.68 | 256.77 |
| stock based compensation to revenue | 0.12 | 0.14 | -14.86 |
| graham number | 8.23 | 9.41 | -12.48 |
| roic | -0.03 | -0.05 | 47.47 |
| return on tangible assets | -0.03 | -0.04 | 20.59 |
| graham net net | 1.83 | 1.72 | 6.50 |
| working capital | 383827000 | 384253000 | -0.11 |
| tangible asset value | 210290000 | 210163000 | 0.06 |
| net current asset value | 157235000 | 157105000 | 0.08 |
| invested capital | 493884000 | 495303000 | -0.29 |
| average receivables | 72437000 | 75595500 | -4.18 |
| average payables | 21623500 | 22073000 | -2.04 |
| average inventory | 123254000 | 123442500 | -0.15 |
| days sales outstanding | 65.57 | 64.18 | 2.17 |
| days payables outstanding | 56.6 | 56.26 | 0.60 |
| days of inventory on hand | 335.55 | 309.28 | 8.50 |
| receivables turnover | 1.37 | 1.4 | -2.12 |
| payables turnover | 1.59 | 1.6 | -0.59 |
| inventory turnover | 0.27 | 0.29 | -7.83 |
| roe | -0.06 | -0.07 | 21.44 |
| capex per share | 0.07 | 0.07 | 4.70 |
ROE: Return on Equity (ROE) increased to -0.06 on 2024-09-30 Q3 from -0.07 on 2024-06-30 Q2, representing a change of 21.44%. However, ROE is <= 5%, suggesting that the company has not been generating high returns for its shareholders.
Current Ratio: Current Ratio increased to 5.02 on 2024-09-30 Q3 from 4.77 on 2024-06-30 Q2, representing a change of 5.31%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -3.40 on 2024-09-30 Q3 from -4.06 on 2024-06-30 Q2, representing a change of 16.30%. Indicating an increase in the relative valuation of the company's stock.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.90 on 2024-09-30 Q3 from 0.80 on 2024-06-30 Q2, representing a change of 13.16%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
None
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2024-11-15 09:30:21
NVRO's HFX iQ SCS system receives CE Mark Certification in Europe. Nevro expects to begin launching HFX iQ in select European countries from the first quarter of 2025.
Sentiment: Positive
Publish Date: 2024-11-15 08:30:00
REDWOOD CITY, Calif. , Nov. 15, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on November 7, 2024, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 37,726 shares of Nevro's common stock to 24 new non-executive employees to induce them to accept employment with Nevro.
Sentiment: Negative
Publish Date: 2024-11-12 12:05:14
NVRO's third-quarter earnings beat its Zacks Consensus Estimate, while worldwide revenues decline year over year. The company continues to incur losses at the operating level.
Sentiment: Neutral
Publish Date: 2024-11-12 07:00:00
HFX iQ is the first and only spinal cord stimulation (SCS) system integrating high-frequency SCS landmark evidence with cloud data insights, leading the way for personalized, data-driven patient care* REDWOOD CITY, Calif. , Nov. 12, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has received CE Mark Certification in Europe for its HFX iQ™ spinal cord stimulation (SCS) system.
Sentiment: Positive
Publish Date: 2024-11-11 21:11:32
Nevro Corp. (NYSE:NVRO ) Q3 2024 Earnings Conference Call November 11, 2024 4:30 PM ET Company Participants Angie McCabe - Vice President, Investor Relations & Corporate Communications Kevin Thornal - Chief Executive Officer & President Rod MacLeod - Chief Financial Officer Conference Call Participants Chris Pasquale - Nephron Research Shagun Singh - RBC Capital Markets Robbie Marcus - JPMorgan Matt Taylor - Jefferies Brandon Vazquez - William Blair Bill Plovanic - Canaccord Suraj Kalia - Oppenheimer Richard Newitter - Truist Securities David Rescott - Baird Operator Good afternoon. My name is Krista, and I will be your conference operator today.
Sentiment: Negative
Publish Date: 2024-11-11 18:21:10
Nevro (NVRO) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to loss of $0.65 per share a year ago.
Sentiment: Negative
Publish Date: 2024-11-11 16:05:00
Reaffirms Full-Year 2024 Revenue Guidance and Raises Full-Year 2024 Adjusted EBITDA Guidance REDWOOD CITY, Calif. , Nov. 11, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its third-quarter 2024 financial results, reaffirmed its full-year 2024 revenue guidance and raised its full-year 2024 adjusted EBITDA guidance.
Sentiment: Negative
Publish Date: 2024-10-29 16:30:00
Analysis Marks the First Study of Spinal Cord Stimulation to Demonstrate Long-term, Significant, and Clinically Meaningful Reductions in HbA1c and Weight in Study Participants with Painful Diabetic Neuropathy and Type 2 Diabetes REDWOOD CITY, Calif. , Oct. 29, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced the publication of new data in the Journal of Pain Research demonstrating significant, durable pain relief and long-term and clinically meaningful reductions in hemoglobin A1c (HbA1c) and weight in study participants with painful diabetic neuropathy (PDN) and Type 2 diabetes who received 10 kHz high-frequency spinal cord stimulation (SCS) therapy.1 Globally, the number of people with diabetes has quadrupled in the last two decades2, and PDN impacts up to 25% of all people with diabetes.3 PDN can have significant impacts on the quality of life for people living with this condition, with symptoms like numbness, tingling/paresthesia, loss of protective sensation, impaired balance, and reduced response to sensory stimuli.4 Patients typically manage PDN with oral pain medications, but the efficacy of these medications is relatively low and can result in intolerable side effects.5 As a result, people with PDN suffer from significantly reduced health-related quality of life (HRQoL), impaired functionality and other comorbidities like sleep disorders, depression, and anxiety.6 The analysis evaluated 144 patients with Type 2 diabetes and refractory PDN who received 10 kHz SCS therapy during the SENZA-PDN randomized controlled trial (RCT), the largest RCT to evaluate SCS to treat PDN.
Sentiment: Positive
Publish Date: 2024-10-16 16:30:00
REDWOOD CITY, Calif. , Oct. 16, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on October 7, 2024, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 26,088 shares of Nevro's common stock to five new non-executive employees to induce them to accept employment with Nevro.
Sentiment: Negative
Publish Date: 2024-10-10 16:45:00
REDWOOD CITY, Calif. , Oct. 10, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it will release its financial results for the third quarter of 2024 after the market closes on Monday, November 11, 2024.
Sentiment: Positive
Publish Date: 2024-09-26 13:50:18
Strength in NVRO's Senza Platform and business diversification plans raises optimism about the stock.
Sentiment: Positive
Publish Date: 2024-09-25 12:46:18
Nevro announces the FDA approval and limited market release of HFX iQ with HFX AdaptivAI.
Sentiment: Positive
Publish Date: 2024-09-24 08:00:00
HFX AdaptivAI combines insights from over 100,000 patients and more than 100 million data points¹ and leverages artificial intelligence (AI) to deliver responsive and personalized pain relief in real time* REDWOOD CITY, Calif. , Sept. 24, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced the U.S. Food and Drug Administration (FDA) approval and limited market release of HFX iQ™ with HFX AdaptivAI™ – a responsive, personalized pain management platform powering the HFX iQ spinal cord stimulation (SCS) system.
Sentiment: Positive
Publish Date: 2024-09-19 16:30:00
REDWOOD CITY, Calif. , Sept. 19, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on September 7, 2024, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 51,543 shares of Nevro's common stock to 21 new non-executive employees to induce them to accept employment with Nevro.
Sentiment: Positive
Publish Date: 2024-08-28 16:15:00
REDWOOD CITY, Calif. , Aug. 28, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that members of its management team will participate in a "fireside chat" (question-and-answer) session at the Wells Fargo 2024 Healthcare Conference on Friday, September 6, 2024, beginning at 8:45 a.m.
Sentiment: Positive
Publish Date: 2024-08-20 14:05:44
Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
